Drug updated on 3/28/2024
| Dosage Form | Tablet (oral; 100 mg, 200 mg) |
| Drug Class | Hedgehog pathway inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- To treat newly-diagnosed acute myeloid leukemia in combination with low-dose cytarabine, in patients ≥ 75 years of age or with comorbidities that preclude use of intensive induction chemotherapy in conjunction with low-dose cytarabine.
Summary
- Glasdegib (Daurismo) is indicated for the treatment of newly-diagnosed acute myeloid leukemia in combination with low-dose cytarabine, specifically targeting patients who are 75 years or older or those with comorbidities that prevent the use of intensive induction chemotherapy.
- A total of three systematic reviews/meta-analyses were reviewed to gather information about Daurismo's effectiveness and safety profile.
- One review highlighted that targeted therapies like glasdegib combined with hypomethylating agents showed promising results in treating difficult-to-treat populations such as elderly patients and those unfit for standard therapy due to comorbidities.
- Another study discussed how glasdegib was used alongside other new drugs approved for acute myeloid leukemia, including decitabine, azacytidine, venetoclax among others; however it did not provide specific outcomes related to its usage.
- The third study revealed a meta-analysis on treatments involving hypomethylating agents or low-dose cytarabine (LDAC), which could potentially include Daurismo given its indication; this analysis found significant variability between trials but suggested better response rates among younger (<75) compared to older patients (>75).
- Adverse events were more frequent when combining targeted therapies like glasdegib with other agents according to one review; however no specific adverse events associated solely with Daurismo were mentioned across the documents reviewed.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Daurismo (glasdegib) Prescribing Information. | 2023 | Pfizer Inc., New York, NY |